544312 HAMPS

Hamps Bio Share Price

 

 

Start SIP in HAMPS

Start SIP

Performance

  • Low
  • ₹21
  • High
  • ₹22
  • 52 Week Low
  • ₹17
  • 52 Week High
  • ₹54
  • Open Price₹22
  • Previous Close₹20
  • Volume8,000

Investment Returns

  • Over 1 Month -14.29%
  • Over 3 Month -10.6%
  • Over 6 Month + 2.44%
  • Over 1 Year -58.61%

Smart Investing Starts Here Start SIP with Hamps Bio for Steady Growth!

Invest Now

Hamps Bio Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 61.5
  • PEG Ratio
  • -
  • Market Cap Cr
  • 18
  • P/B Ratio
  • 2.2
  • Average True Range
  • 0.82
  • EPS
  • -
  • Dividend Yield
  • 0
  • MACD Signal
  • -0.85
  • RSI
  • 37.55
  • MFI
  • 17.58

Hamps Bio Financials

Hamps Bio Technicals

EMA & SMA

Current Price
₹21.00
+ 1.4 (7.14%)
pointer
  • Bearish Moving Average 9
  • Bullish Moving Average 5
  • 20 Day
  • ₹21.47
  • 50 Day
  • ₹22.93
  • 100 Day
  • ₹24.50
  • 200 Day
  • -

Resistance and Support

19.22 Pivot Speed
  • R3 21.13
  • R2 20.37
  • R1 19.98
  • S1 18.83
  • S2 18.07
  • S3 17.68

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Hamps Bio Ltd. specializes in Pharmaceutical Formulation and Freeze-Dried Ingredients with two core divisions. Operating across Gujarat, Maharashtra, Rajasthan, and Madhya Pradesh, it serves B2B and B2C markets with therapeutic medicines and innovative freeze-dried food products.

Hamps Bio Ltd has an operating revenue of Rs. 17.14 Cr. on a trailing 12-month basis. An annual revenue growth of 5% is not great, Pre-tax margin of 6% is okay, ROE of 3% is fair but needs improvement. The company has a reasonable debt to equity of 23%, which signals a healthy balance sheet. From an O'Neil Methodology perspective, the stock has an EPS Rank of 4 which is a POOR score indicating inconsistency in earnings, a RS Rating of 17 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at D which indicates heavy supply, Group Rank of 166 indicates it belongs to a poor industry group of Medical-Whlsle Drg/Suppl and a Master Score of E is the worst. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment. Please note that this is a thinly traded stock.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Hamps Bio Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2025-11-14 Half Yearly Results (Revised) issue of equity shares in the ratio of 1:1 of Rs. 10/-.
2025-07-29 Bonus issue
2025-05-28 Audited Results
Date Purpose Remarks
2025-09-09 Bonus Rs.0.00 issue of equity shares in the ratio of 1:1 of Rs. 10/-.

Hamps Bio F&O

Hamps Bio Shareholding Pattern

71.99%
0%
24.06%
3.95%

About Hamps Bio

  • NSE Symbol
  • HAMPS
  • BSE Symbol
  • 544312
  • Chairman & Managing Director
  • Mr. Herrik Mountbaton Shah
  • ISIN
  • INE0QBD01018

Similar Stocks to Hamps Bio

Hamps Bio FAQs

Hamps Bio share price is ₹21 As on 26 December, 2025 | 15:51

The Market Cap of Hamps Bio is ₹18.3 Cr As on 26 December, 2025 | 15:51

The P/E ratio of Hamps Bio is 61.5 As on 26 December, 2025 | 15:51

The PB ratio of Hamps Bio is 2.2 As on 26 December, 2025 | 15:51

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23